CareDx, Inc. (NASDAQ:CDNA) Director Sells $202,521.20 in Stock

CareDx, Inc. (NASDAQ:CDNA - Get Free Report) Director Hannah Valantine sold 10,570 shares of the firm's stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $19.16, for a total transaction of $202,521.20. Following the completion of the transaction, the director now owns 38,994 shares in the company, valued at $747,125.04. The trade was a 21.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

CareDx Trading Down 0.5%

CareDx stock traded down $0.09 during midday trading on Monday, hitting $18.95. The stock had a trading volume of 730,877 shares, compared to its average volume of 907,962. The business has a fifty day moving average price of $17.57 and a 200 day moving average price of $20.00. CareDx, Inc. has a 12 month low of $13.81 and a 12 month high of $34.84. The stock has a market cap of $1.06 billion, a P/E ratio of 16.48 and a beta of 2.18.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The firm had revenue of $84.69 million for the quarter, compared to analysts' expectations of $84.56 million. During the same quarter last year, the company posted ($0.03) earnings per share. CareDx's revenue was up 17.6% on a year-over-year basis. On average, equities analysts anticipate that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CDNA. Stephens restated an "overweight" rating and issued a $40.00 price target on shares of CareDx in a report on Monday, May 5th. The Goldman Sachs Group cut their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Wall Street Zen downgraded CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $25.00 target price on shares of CareDx in a research report on Monday, May 5th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $30.33.

Institutional Investors Weigh In On CareDx

A number of hedge funds have recently added to or reduced their stakes in the stock. Voya Investment Management LLC lifted its stake in CareDx by 12.8% in the first quarter. Voya Investment Management LLC now owns 24,400 shares of the company's stock valued at $433,000 after buying an additional 2,761 shares during the last quarter. Strs Ohio bought a new stake in CareDx in the first quarter valued at $462,000. Acadian Asset Management LLC lifted its stake in CareDx by 6.1% in the first quarter. Acadian Asset Management LLC now owns 359,303 shares of the company's stock valued at $6,373,000 after buying an additional 20,806 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in CareDx by 11.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company's stock valued at $2,378,000 after buying an additional 13,619 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in CareDx by 18.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company's stock valued at $19,703,000 after buying an additional 170,504 shares during the last quarter.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.